Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13451 - 13475 of 14390 in total
Investigational
CNDO-109 are CNDO-109-activated allogeneic natural killer cells.
Investigational
G305 is a recombinant NY-ESO-1 protein plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with LV305.
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Maveropepimut-S is a T cell activating immunotherapy.
Investigational
ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Obecabtagene autoleucel is an investigational autologous CD19 CAR T cell therapy.
Investigational
AMG-119 are CAR-T cells targeting delta-like ligand 3 (DLL3).
Investigational
Gavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex.
Investigational
TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.[L44281,L44286]
Investigational
Displaying drugs 13451 - 13475 of 14390 in total